Morten Lindhardt1, Frederik Persson1, Petra Zürbig2, Angelique Stalmach3, Harald Mischak2,3, Dick de Zeeuw4, Hiddo Lambers Heerspink4, Ronald Klein5, Trevor Orchard6, Massimo Porta7, John Fuller8, Rudolf Bilous9,10, Nish Chaturvedi11, Hans-Henrik Parving12, Peter Rossing1,13,14. 1. Steno Diabetes Center, Gentofte, Denmark. 2. Mosaiques Diagnostics GmbH, Hannover, Germany. 3. University of Glasgow, Glasgow, UK. 4. Department of Clinical Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 5. Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 6. Department of Epidemiology, Medicine & Pediatrics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. 7. Department of Medical Sciences, University of Turin, Torino, Italy. 8. Department of Epidemiology and Public Health, University College London, London, UK. 9. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. 10. South Tees NHS Trust, Middlesbrough, UK. 11. Institute of Cardiovascular Sciences, University College London, London, UK. 12. Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 13. Faculty of Health Science, University of Aarhus, Aarhus, Denmark. 14. The Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND: Early prevention of diabetic nephropathy is not successful as early interventions have shown conflicting results, partly because of a lack of early and precise indicators of disease development. Urinary proteomics has shown promise in this regard and could identify those at high risk who might benefit from treatment. In this study we investigate its utility in a large type 2 diabetic cohort with normoalbuminuria. METHODS: We performed a post hoc analysis in the Diabetic Retinopathy Candesartan Trials (DIRECT-Protect 2 study), a multi centric randomized clinical controlled trial. Patients were allocated to candesartan or placebo, with the aim of slowing the progression of retinopathy. The secondary endpoint was development of persistent microalbuminuria (three of four samples). We used a previously defined chronic kidney disease risk score based on proteomic measurement of 273 urinary peptides (CKD273-classifier). A Cox regression model for the progression of albuminuria was developed and evaluated with integrated discrimination improvement (IDI), continuous net reclassification index (cNRI) and receiver operating characteristic curve statistics. RESULTS: Seven hundred and thirty-seven patients were analysed and 89 developed persistent microalbuminuria (12%) with a mean follow-up of 4.1 years. At baseline the CKD273-classifier predicted development of microalbuminuria during follow-up, independent of treatment (candesartan/placebo), age, gender, systolic blood pressure, urine albumin excretion rate, estimated glomerular filtration rate, HbA1c and diabetes duration, with hazard ratio 2.5 [95% confidence interval (CI) 1.4-4.3; P = 0.002] and area under the curve 0.79 (95% CI 0.75-0.84; P < 0.0001). The CKD273-classifier improved the risk prediction (relative IDI 14%, P = 0.002; cNRI 0.10, P = 0.043). CONCLUSIONS: In this cohort of patients with type 2 diabetes and normoalbuminuria from a large intervention study, the CKD273-classifier was an independent predictor of microalbuminuria. This may help identify high-risk normoalbuminuric patients for preventive strategies for diabetic nephropathy.
BACKGROUND: Early prevention of diabetic nephropathy is not successful as early interventions have shown conflicting results, partly because of a lack of early and precise indicators of disease development. Urinary proteomics has shown promise in this regard and could identify those at high risk who might benefit from treatment. In this study we investigate its utility in a large type 2 diabetic cohort with normoalbuminuria. METHODS: We performed a post hoc analysis in the Diabetic Retinopathy Candesartan Trials (DIRECT-Protect 2 study), a multi centric randomized clinical controlled trial. Patients were allocated to candesartan or placebo, with the aim of slowing the progression of retinopathy. The secondary endpoint was development of persistent microalbuminuria (three of four samples). We used a previously defined chronic kidney disease risk score based on proteomic measurement of 273 urinary peptides (CKD273-classifier). A Cox regression model for the progression of albuminuria was developed and evaluated with integrated discrimination improvement (IDI), continuous net reclassification index (cNRI) and receiver operating characteristic curve statistics. RESULTS: Seven hundred and thirty-seven patients were analysed and 89 developed persistent microalbuminuria (12%) with a mean follow-up of 4.1 years. At baseline the CKD273-classifier predicted development of microalbuminuria during follow-up, independent of treatment (candesartan/placebo), age, gender, systolic blood pressure, urine albumin excretion rate, estimated glomerular filtration rate, HbA1c and diabetes duration, with hazard ratio 2.5 [95% confidence interval (CI) 1.4-4.3; P = 0.002] and area under the curve 0.79 (95% CI 0.75-0.84; P < 0.0001). The CKD273-classifier improved the risk prediction (relative IDI 14%, P = 0.002; cNRI 0.10, P = 0.043). CONCLUSIONS: In this cohort of patients with type 2 diabetes and normoalbuminuria from a large intervention study, the CKD273-classifier was an independent predictor of microalbuminuria. This may help identify high-risk normoalbuminuric patients for preventive strategies for diabetic nephropathy.
Authors: Insa M Schmidt; Suraj Sarvode Mothi; Parker C Wilson; Ragnar Palsson; Anand Srivastava; Ingrid F Onul; Zoe A Kibbelaar; Min Zhuo; Afolarin Amodu; Isaac E Stillman; Helmut G Rennke; Benjamin D Humphreys; Sushrut S Waikar Journal: Clin J Am Soc Nephrol Date: 2021-11-10 Impact factor: 8.237
Authors: Manuel Wallbach; Petra Zürbig; Hassan Dihazi; Gerhard A Müller; Rolf Wachter; Joachim Beige; Michael J Koziolek; Harald Mischak Journal: J Clin Hypertens (Greenwich) Date: 2018-09-10 Impact factor: 3.738
Authors: Jong Ho Kim; Seo Young Oh; Eun Heui Kim; Min Jin Lee; Yun Kyung Jeon; Bo Hyun Kim; Jin Mi Kim; Yong Ki Kim; Sang Soo Kim; In Joo Kim Journal: Diabetol Metab Syndr Date: 2017-09-06 Impact factor: 3.320
Authors: Gemma E Currie; Bernt Johan von Scholten; Sheon Mary; Jose-Luis Flores Guerrero; Morten Lindhardt; Henrik Reinhard; Peter K Jacobsen; William Mullen; Hans-Henrik Parving; Harald Mischak; Peter Rossing; Christian Delles Journal: Cardiovasc Diabetol Date: 2018-04-06 Impact factor: 9.951
Authors: Gabriel Velez; Peter H Tang; Thiago Cabral; Galaxy Y Cho; Daniel A Machlab; Stephen H Tsang; Alexander G Bassuk; Vinit B Mahajan Journal: Transl Vis Sci Technol Date: 2018-09-26 Impact factor: 3.283
Authors: Hee-Sung Ahn; Jong Ho Kim; Hwangkyo Jeong; Jiyoung Yu; Jeonghun Yeom; Sang Heon Song; Sang Soo Kim; In Joo Kim; Kyunggon Kim Journal: Int J Mol Sci Date: 2020-06-14 Impact factor: 5.923
Authors: María E Rodríguez-Ortiz; Claudia Pontillo; Mariano Rodríguez; Petra Zürbig; Harald Mischak; Alberto Ortiz Journal: Sci Rep Date: 2018-10-29 Impact factor: 4.379